[钆类磁共振造影剂在多发性硬化症中的应用的药物经济学分析]

[The pharmacological economic analysis of application of magnetic resonance contrast mediums containing gadolinium in case of multiple sclerosis].

作者信息

Shegay M M, Shimanovsky D N

机构信息

N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia.

I. M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University), 119991, Moscow, Russia,

出版信息

Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2021 Mar;29(2):343-346. doi: 10.32687/0869-866X-2021-29-2-343-346.

DOI:10.32687/0869-866X-2021-29-2-343-346

PMID:33901380

Abstract

UNLABELLED

The article considers issues of pharmacoeconomics of applying gadolinium-containing contrast medium in diagnostic of multiple sclerosis in patients.

MATERIALS AND METHODS

The MS Excel calculator was applied to estimate costs and analyze impact on the budget under treatment of multiple sclerosis exacerbations, that were diagnosed using various gadolinium-containing contrast mediums. The direct medical costs for diagnostics with gadolinium-containing contrast medium and hospitalization due to exacerbation in accordance with mandatory medical insurance system were taken into account.

THE RESULTS

At the expense of reducing number of multiple sclerosis exacerbations due to the use of single-molar gadolinium-containing contrast medium (gadobutrol) as compared with semi-polar gadolinium-containing contrast medium (gadodiamide, gadoteric acid and gadoteridol) in 1000 patients it is possible to reduce financial expenses from 1,968,642 to 7,175,520 RUB.

CONCLUSION

The cost of magnetic resonance imaging diagnostics with contrast enhancement and treatment of multiple sclerosis exacerbations increases in the series: gadobutrol < gadodiamide (Jodas Expoim) < gadodiamide (GE Health Care) < gadoteridol < gadoteric acid.

摘要